Assignee
OXFORD BIOTHERAPEUTICS LTD
GB·7 granted patents·16 pending applications·27 citations·filing 2009–2024
Top patents by PatentIndex Score
23 records- 0193US9732160B2Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1OXFORD BIOTHERAPEUTICS LTD·Filed 2015·Granted Aug 15, 2017·8 cites·7 claims
- 0289US9175092B2Antibodies to bone marrow stromal antigen 1OXFORD BIOTHERAPEUTICS LTD·Filed 2013·Granted Nov 3, 2015·5 cites·14 claims
- 0384US10081682B2Conjugated antibodies against LY75 for the treatment of cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2014·Granted Sep 25, 2018·8 cites·21 claims
- 0481US10239956B2Nucleic acid encoding bone marrow stromal antigen 1 antibodyOXFORD BIOTHERAPEUTICS LTD·Filed 2017·Granted Mar 26, 2019·1 cites·12 claims
- 0581US2025163174A1Conjugated antibodies against ly75 for the treatment of cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0680US9932411B2AntibodiesOXFORD BIOTHERAPEUTICS LTD·Filed 2014·Granted Apr 3, 2018·5 cites·24 claims
- 0770US10982005B2Antibodies to bone marrow stromal antigen 1OXFORD BIOTHERAPEUTICS LTD·Filed 2019·Granted Apr 20, 2021·0 cites·11 claims
- 0868US2021371541A1Conjugated antiboides against ly75 for the treatment of cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 0965US2019310255A1ProteinsOXFORD BIOTHERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1060US2024228649A9Crtam antibodies and methods of treating cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1160US2021346512A1Ly75 as cancer therapeutic and diagnostic targetOXFORD BIOTHERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 1259US2024254238A1Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitorOXFORD BIOTHERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1358US2018246114A1Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2018·Application pending·0 cites
- 1457US2014024048A1ProteinOXFORD BIOTHERAPEUTICS LTD·Filed 2013·Application pending·0 cites
- 1551US2011229480A1Pta072 proteinOXFORD BIOTHERAPEUTICS LTD·Filed 2009·Application pending·0 cites
- 1650US2011110859A1ProteinOXFORD BIOTHERAPEUTICS LTD·Filed 2010·Application pending·0 cites
- 1748US2019317100A1Ly75 as cancer therapeutic and diagnostic targetOXFORD BIOTHERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1846US11673963B2CRTAM antibodies and methods of treating cancerOXFORD BIOTHERAPEUTICS LTD·Filed 2018·Granted Jun 13, 2023·0 cites·18 claims
- 1946US2015297743A1Ly75 as cancer therapeutic and diagnostic targetOXFORD BIOTHERAPEUTICS LTD·Filed 2013·Application pending·0 cites
- 2042US2016039933A1Antibodies specific to cadherin-17OXFORD BIOTHERAPEUTICS LTD·Filed 2015·Application pending·0 cites
- 2139US2022372137A1Antibodies and methods of useOXFORD BIOTHERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2237US2015210770A1Therapeutic and diagnostic targetOXFORD BIOTHERAPEUTICS LTD·Filed 2013·Application pending·0 cites
- 2331US2016002351A1Inactive n-acetylated-alpha-linked acidic dipeptidase-like protein 2 (naaladl2) as a therapeutic and diagnostic targetOXFORD BIOTHERAPEUTICS LTD·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when OXFORD BIOTHERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →